What’s New in Interventional Spine Biologics? Studies from TOBI Faculty

Mar 13

What’s New in Interventional Spine Biologics? Studies from TOBI Faculty

This year TOBI has added a workshop and cadaver lab track: Interventional Spine/Pain Management Biologics. Catch up with our Faculty publications in spine before joining us in June at TOBI 2017:

22 Feb 2018; Oxford University Press: Pain Medicine
Increased Nuclear T2 Signal Intensity and Improved Function and Pain in a Patient One Year After an Intradiscal Platelet–Rich Plasma Injection
Dr. Gregory Lutz of the Hospital for Special Surgery continues his remarkable research on intradiscal platelet-rich plasma (PRP) injections in this new publication in the Oxford University Press’ Pain Medicine. Dr. Lutz will be discussing and teaching his research further at TOBI 2017, both at the Symposium podium and in the workshop & hands-on cadaver lab.
See the full study here.

January 2017, Journal of Translational Medicine
Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease
Stromal vascular fraction (SVF) can easily be obtained from a mini-lipoaspirate procedure of fat tissue and platelet rich plasma (PRP) can be obtained from peripheral blood. The SVF contains a mixture of cells including ADSCs and growth factors and has been depleted of the adipocyte (fat cell) population. In this study, TOBI faculty alumni Kristin Comella, PhD, evaluated the safety and efficacy of administering SVF and PRP intra-discally into patients with degenerative disc disease.
Access the study here.

27 Nov 2016; Physical Medicine and Rehabilitation Clinics of North America
Regenerative Treatments for Spinal Conditions
This is a literature review of clinical and translational studies, performed to provide an overview of current concepts on regenerative treatments for spinal conditions, including platelet rich plasma and stem cell treatments to treat low back pain, done by TOBI 2017 Speakers & Faculty Gregory Lutz, MD, of the Hospital for Special Surgery.
See the full study here.

1 Sep 2016; Journal of Translational Medicine
Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: a long-term safety and feasibility study.
TOBI Faculty Christopher Centeno, MD, alumni Jonthan R. Schultz, MD, and Faculty Gregory Lutz, MD, co-authored this study on intradiscal injections of  bone marrow-derived mesenchymal stem cells (MSCs).  These MSCs are multipotent and exhibit great tissue regenerative potential including bone, cartilage, and fibrous tissue regeneration. Their early human clinical data suggests the safety and feasibility of the clinical use of hypoxic cultured bone marrow-derived mesenchymal stem cells for the treatment of lower back pain due to degenerative disc disorders and support further studies utilizing hypoxic cultured bone marrow-derived stem cells. The overall improvements reported are encouraging, but a larger double-blind, controlled, randomized clinical study with significant number of patients and implementation of validated endpoint measurements are next steps in order to demonstrate efficacy of this cell-based biologic.
See the full study here.


For the latest orthobiologics research and best practices from global field leaders, join us at TOBI 2017:

The Orthobiologic Institute (TOBI)
7th Annual PRP & Regenerative Medicine Symposium with Workshops & Cadaver Labs (TOBI 2017)
June 8-10, 2017
Wynn, Las Vegas, NV


Comments are closed.